EGFR and non-small cell lung carcinoma: The OCEAN study was a two-cohort trial showing the efficacy of osimertinib in achieving BM response rate (BMRR) in RT-naïve patients with T790M EGFR mutated NSCLC especially in the presence of exon 19 deletion [43].